At the end of March, Sage Therapeutics announced FDA approval for the intravenous and hospital-supervised use of their new postpartum depression (PPD) drug, Zulresso (brexanlone). The possibility of a new way to help women who are struggling with depression after childbirth is an exciting and important development, especially with claims that around 11% of new… Read more →